We are live on
!
Find out more
ACM
Aquilo Capital Management Portfolio holdings
AUM
$55.8M
1-Year Est. Return
41.76%
This Fund
S&P 500
This Quarter
Est. Return
-19.62%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$66.3M
AUM Growth
-$65.6M
(-50%)
Cap. Flow
-$44.5M
Cap. Flow
% of AUM
-67.11%
Top 10 Holdings %
Top 10 Hldgs %
88.56%
Holding
17
New
3
Increased
6
Reduced
5
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Protagonist Therapeutics
PTGX
|
+$3.34M |
| 2 |
Precision BioSciences
DTIL
|
+$1.13M |
| 3 |
RPTX
Repare Therapeutics
RPTX
|
+$906K |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
+$857K |
| 5 |
SLN
Silence Therapeutics
SLN
|
+$645K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRUS
Merus
MRUS
|
+$5.89M |
| 2 |
Regenxbio
RGNX
|
+$5.49M |
| 3 |
Sutro Biopharma
STRO
|
+$2.33M |
| 4 |
Arrowhead Research
ARWR
|
+$1.82M |
| 5 |
Arvinas
ARVN
|
+$1.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Arrowhead Research
ARWR
$12.4B
| $13.3M | 20.06% |
707,589
-88,224
| -11% | -$1.82M |
|
|
BPMC
2
DELISTED
Blueprint Medicines
BPMC
| $11.3M | 17.04% |
129,600
+5,000
| +4% | +$458K |
|
3
Kymera Therapeutics
KYMR
$8.94B
| $7.38M | 11.13% |
183,521
-25,222
| -12% | -$1.14M |
|
4
CALL
Amgen
AMGN
$222B
| $6.52M | 9.83% |
+25,000
| New | +$7.42M |
|
|
5
Arvinas
ARVN
$572M
| $6.3M | 9.5% |
328,766
-60,000
| -15% | -$1.46M |
|
|
BCYC
6
Bicycle Therapeutics
BCYC
$292M
| $3.11M | 4.68% |
221,911
+40,000
| +22% | +$857K |
|
|
7
Protagonist Therapeutics
PTGX
$9.44B
| $2.96M | 4.46% |
+76,592
| New | +$3.34M |
|
|
8
Regenxbio
RGNX
$708M
| $2.68M | 4.04% |
346,302
-584,406
| -63% | -$5.49M |
|
9
Immatics
IMTX
$1.32B
| $2.66M | 4.01% |
373,902
+40,400
| +12% | +$347K |
|
|
SLN
10
Silence Therapeutics
SLN
$564M
| $2.53M | 3.81% |
367,214
+50,000
| +16% | +$645K |
|
11
Adicet Bio
ACET
$74.7M
| $2.44M | 3.67% |
158,200
| – | – |
|
|
12
Precision BioSciences
DTIL
$207M
| $2.04M | 3.08% |
536,376
+154,573
| +40% | +$1.13M |
|
|
RPTX
13
DELISTED
Repare Therapeutics
RPTX
| $1.69M | 2.56% |
1,293,715
+304,351
| +31% | +$906K |
|
|
14
CALL
Arrowhead Research
ARWR
$12.4B
| $1.41M | 2.13% |
+75,000
| New | +$1.54M |
|
|
15
Sutro Biopharma
STRO
$421M
| $916 | ﹤0.01% |
50
-76,200
| -100% | -$2.33M |
|
|
MRUS
16
DELISTED
Merus
MRUS
| – | – |
-117,855
| Closed | -$5.89M |
|
17
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
| – | – |
-75,000
| Closed | -$43M |
|
Similar funds
VCM
YEPV
HWP
GIS
AA
PGIM
RGMC
PAM
Aquilo Capital Management's Q4 2024 Portfolio in Review
As of Q4 2024, Aquilo Capital Management held 17 positions worth $66.3M, down 50% from $132M the previous quarter. Its ten largest holdings account for 89% of the portfolio.
Aquilo Capital Management withdrew a net $44.5M in Q4 2024, closing 2 positions and reducing 5 holdings. Its most notable exit was Merus, an estimated $5.89M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 67% a quarter earlier.
Against the trend, Aquilo Capital Management opened a new position in Protagonist Therapeutics worth $2.96M.
- Aquilo Capital Management's largest Q4 2024 buy was Protagonist Therapeutics: 76,592 shares worth $2.96M.
- Aquilo Capital Management added most to Precision BioSciences in Q4 2024, an estimated $1.13M increase.
- Aquilo Capital Management's biggest Q4 2024 reduction was Regenxbio, cutting an estimated $5.49M.
- Aquilo Capital Management fully exited Merus in Q4 2024, selling an estimated $5.89M.
- Aquilo Capital Management's ten largest holdings make up 89% of its $66.3M portfolio in Q4 2024.
- Aquilo Capital Management opened 3 new positions and closed 2 in Q4 2024.
- Aquilo Capital Management's portfolio value fell 50% quarter-over-quarter to $66.3M.
Based on Aquilo Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.